

SALSA: Self-Administered Lidocaine Gel for Pain Management with First Trimester Surgical Abstortion

A Randomized Trial

Paul D Blumenthal, MD, MPH





Background

- Pain is a limiting factor in where and how abortion is performed
 - **ACCESS** issue
 - Pain management has not been woman centered
- 84% of providers employ a lidocaine paracervical block (PCB)
 - Non-standardized approach
 - PCB itself can be painful



Clinical Question

- Can we achieve adequate pain relief through self-administered, non-invasive means alone?
- Should we wait longer between lidocaine administration and procedure start time?

Study Objectives



- To compare pain control using a locally-applied, self-administered lidocaine gel with PCB
- To increase pain control options
- Hypothesis:

Patients who receive lidocaine gel applied 20-30 minutes prior to first trimester surgical abortion will have pain control that is *no worse than* that of a traditional paracervical block



Study Design

- Open label, RCT
- Non-inferiority design
- 20ml of 2% lidocaine HCl vaginally (400mg)
20-30 minutes prior to procedure






Study Design

Paracervical Block Technique:

- 12 mL of 1% lidocaine (120 mg) with epinephrine
- 2 mL injected at tenaculum site
- Tenaculum immediately placed
- 10 mL injected into cervicovaginal junction at 4 and 8 o'clock



Lidocaine Dose




- Serum toxicity of intracervical lidocaine: 5 mcg/ml [Blanco 1982]
- Serum lidocaine levels 10 minutes after paracervical injection of 20 ml of 1% lidocaine (200mg) found mean blood levels of 0.9 to 1.61 mcg/ml [McKenzie 1978]
- Serum lidocaine levels following 4ml of 10% lidocaine spray (400mg) prior to intracavitary vaginal brachytherapy found non-toxic levels & adequate pain relief [Chen 1998]

Gel Protocol



Gel Protocol



Study Design



- Inclusion criteria
 - ≥ 18 years
 - 5 - 11w5d gestation
 - English or Spanish speaking
- Exclusion criteria
 - Preoperative misoprostol
 - PO pain medication instead of iv
 - Allergy to lidocaine, midazolam, fentanyl
 - Known uterine anomaly or cervical procedure
 - Inability to use tampons



Recruitment & Allocation

- Block randomization
- Intention to treat
- Open label
 - versus single blinded with (sham PCB + gel) and (PCB + KY jelly)
 - » Ineffective blinding (Renner, et al)



Outcomes

Primary Outcome:

Pain perceived by VAS (0-100 mm) at time of **cervical dilation**

Visual Analog Scale (VAS)*



Outcomes



Secondary Outcomes:

Pain perceived at additional time points:

- Anticipated pain: 30 minutes prior to procedure
- Baseline pain: arrival to procedure room
- After speculum placement
- After tenaculum placement
- At procedure completion, after speculum removal
- In recovery: 30-45 minutes after procedure



Results: Demographics

- No significant differences between groups





	Lidocaine Paracervical Block <i>n</i> =68	Self-administered Lidocaine Gel <i>n</i> =69	p value
<i>f</i>			
Type of Procedure			.81*
MVA	59 (86.8%)	58 (84.1%)	
EVA	9 (13.2%)	11 (15.9%)	
Maximum Dilation (mm)			
Mean (\pm SD)	8.21 \pm 1.6	7.72 \pm 1.6	.09*
Median (Range)	8 (6-12)	7 (6-11)	.08 [†]
Time between gel insertion and speculum placement (min:seconds)			
Mean (\pm SD)	--	39:02 \pm 14:20	
Median (Range)	--	37:10 (15:00-86:00)	
Time between paracervical block and cervical dilation (min:seconds)			
Mean (\pm SD)	1:07 \pm 1:04	--	
Median (Range)	1:00 (0:20-4:00)	--	
Total Procedure Time (min:seconds)			
Median (Range)	7:16 (3:00-16:07)	5:23 (2:20-15:38)	.000 [†]


^a Fisher's Exact Test

^b Student's *t* test

^c Mann-Whitney *U*-test



Figure 2. Box plot of pain scores (VAS) at various time points, medians displayed





	Median		p-value	Mean		p-value
	PCB mm (range)	Gel mm (range)		PCB mm (± S.D.)	Gel mm (± S.D.)	
All Subjects	<i>n</i> =68	<i>n</i> =69		<i>n</i> =68	<i>n</i> =69	
Cervical Dilation	65 (10-100)	68 (17-97)	.45 ^a	60.12 (± 24.18)	64.07 (± 20.85)	.31 ^b
Nulliparous Subjects	<i>n</i> =40	<i>n</i> =44		<i>n</i> =40	<i>n</i> =44	
Cervical Dilation	64.5 (10-96)	69 (20-96)	.24 ^a	58.15 (± 24.15)	65.57 (± 19.59)	.12 ^b
Parous Subjects	<i>n</i> =28	<i>n</i> =25		<i>n</i> =28	<i>n</i> =25	
Cervical Dilation	65.5 (11-100)	66 (17-97)	.86 ^a	62.93 (± 24.38)	61.44 (± 23.08)	.82 ^b

^a Mann-Whitney *U*-test

^b Student's *t* test

Acceptability





Limitations

- Non-blinded
- Exclusion of PO sedation patients



Strengths

- Generalizability to other GYN procedures
 - Intra-Uterine Device insertions
 - Endometrial biopsies
 - Hysteroscopy

Part II: **SALUD**
(Self-Administered
Lidocaine for
Uterine Devices)



Thank You

- Dr. Jennifer Conti
- Dr. Kate Shaw
- Klaira Lerma
- Corinne Montgomery
- Planned Parenthood Mar Monte & Stanford Gynecology clinic staff



Questions?





References

- 1. Facts on Induced Abortion Worldwide. January 2012 [cited December 20, 2015]; Available from: http://www.guttmacher.org/pubs/fb_IAW.html
- 2. Facts on Induced Abortion in the United States. July 2014 [cited December 20, 2015]; Available from: http://www.guttmacher.org/pubs/fb_induced_abortion.html
- 3. Chapter 8: Pain Management. In: Paul M, Lichtenberg PM, Borgatta L, Grimes D, Sutbbblefield, P. G., Creinin, M., editors. Management of unintended and abnormal pregnancy: Comprehensive abortion care. Hoboken, NJ: Blackwell Publishing, LTD; 2009. p. 90-110.
- 4. Belanger E, Melzack R, Lauzon P. Pain of first-trimester abortion: a study of psychosocial and medical predictors. *Pain* 1989 Mar;36(3):339-50.
- 5. Renner RM, Jensen JT, Nichols MD, Edelman AB. Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. *Contraception* 2010 May;81(5):372-88.
- 6. O'Connell K, Jones HE, Simon M, Saporta V, Paul M, Lichtenberg ES, et al. First-trimester surgical abortion practices: a survey of National Abortion Federation members. *Contraception* 2009 May;79(5):385-92.
- 7. Renner RM, Nichols MD, Jensen JT, Li H, Edelman AB. Paracervical block for pain control in first-trimester surgical abortion: a randomized controlled trial. *Obstet Gynecol* 2012 May;119(5):1030-7.
- 8. Li HW, Wong CY, Lo SS, Fan SY. Effect of local lignocaine gel application for pain relief during suction termination of first-trimester pregnancy: a randomized controlled trial. *Hum Reprod* 2006 Jun;21(6):1461-6.
- 9. Karasahin KE, Alanbay I, Ercan CM, Mesten Z, Simsek C, Baser I. Lidocaine spray in addition to paracervical block reduces pain during first-trimester surgical abortion: a placebo-controlled clinical trial. *Contraception* 2011 Apr;83(4):362-6.
- 10. Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. *J Pain* 2003 Sep;4(7):407-14.
- 11. Rowbotham MC. What is a "clinically meaningful" reduction in pain? *Pain* 2001 Nov;94(2):131-2.
- 12. Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. *Ann Emerg Med* 1996 Apr;27(4):485-9.
- 13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009 Apr;42(2):377-81.
- 14. Richardson SJ, Brooks HL, Bramley G, Coleman JJ. Evaluating the effectiveness of self-administration of medication (SAM) schemes in the hospital setting: a systematic review of the literature. *PLoS One* 2014;9(12):e113912.
- 15. Blanco LJ, Reid PR, King TM. Plasma lidocaine levels following paracervical infiltration for aspiration abortion. *Obstet Gynecol* 1982 Oct;60(4):506-8.
- 16. Chen HC, Leung SW, Wang CJ, Sun LM, Fang FM, Huang EY, et al. Local vaginal anesthesia during high-dose-rate intracavitary brachytherapy for cervical cancer. *Int J Radiat Oncol Biol Phys* 1998 Oct 1;42(3):541-4.
- 17. McKenzie R, Shaffer WL. A safer method for paracervical block in therapeutic abortions. *Am J Obstet Gynecol* 1978 Feb 1;130(3):317-20.




Analysis

Statistical methods:

- Demographic characteristics compared using Chi-square test or Student's *t*-test
- Student's *t*-test to evaluate primary outcome of pain at cervical dilation
- Median VAS scores analyzed using nonparametric tests.
- Multivariate analyses to evaluate potential confounders and determine independent predictors of pain at the time of cervical dilation

Results





Methods

Sample size calculation:

- Delta = 15% difference in VAS*
- Standard deviation of VAS = 26mm**
- $\alpha=0.025$ & $\beta=0.10$, 90% power
- 142 participants (71 per group)